NEW YORK, August 10, 2017 /PRNewswire/ --
If you want a Stock Review on DERM, ECYT, FGEN, or GBT then come over to
On Wednesday, shares in Menlo Park, California headquartered Dermira Inc. recorded a trading volume of 946,041 shares. The stock ended the session 0.58% higher at $22.56. The stock is trading below its 50-day moving average by 20.80%. Moreover, shares of Dermira, which engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the US, have a Relative Strength Index (RSI) of 21.41. Visit us today and download your complete report on DERM for free at:
West Lafayette, Indiana headquartered Endocyte Inc.'s stock closed the day 4.93% lower at $1.35 with a total trading volume of 800,395 shares. The stock is trading below its 50-day moving average by 14.25%. Additionally, shares of Endocyte, which develops targeted therapies for the treatment of cancer and inflammatory diseases in the US, have an RSI of 36.90. The complimentary research report on ECYT can be accessed at:
Shares in San Francisco, California headquartered FibroGen Inc. recorded a trading volume of 2.42 million shares, which was above their three months average volume of 575.32 thousand shares. The stock ended yesterday's trading session 11.82% lower at $43.65. The Company's shares have advanced 30.49% in the past month, 59.89% over the previous three months, 127.46% in the past twelve months, and 103.97% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 34.98% and 69.16%, respectively. Furthermore, shares of FibroGen, which discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the US, have an RSI of 65.98.
On August 08th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $38 a share to $80 a share. Register for free on DailyStockTracker.com and download the research report on FGEN at:
Global Blood Therapeutics
South San Francisco, California headquartered Global Blood Therapeutics Inc.'s stock finished Wednesday's session 0.37% higher at $27.05 with a total trading volume of 510,537 shares. The Company's shares have advanced 50.44% in the past twelve months and 87.20% since the start of this year. The stock is trading above its 200-day moving average by 7.98%. Additionally, shares of Global Blood Therapeutics, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 46.14.
On August 08th, 2017, research firm JP Morgan reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $44 a share to $46 a share. Get free access to your research report on GBT at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All